Dexcom (DXCM) EBIT (2010 - 2026)

Dexcom (DXCM) has 17 years of EBIT data on file, last reported at $255.3 million in Q1 2026.

• On a quarterly basis, EBIT rose 90.95% year-over-year to $255.3 million in Q1 2026; TTM through Mar 2026 was $1.0 billion, a 63.36% increase from a year earlier, with the FY2025 full-year figure at $911.8 million, up 51.97% from the prior year.
• EBIT for Q1 2026 stood at $255.3 million, down from $323.0 million in the prior quarter.
• Over the last five years, EBIT for DXCM reached as high as $323.0 million in Q4 2025 and fell as low as $41.3 million in Q1 2022.
• Historically, EBIT has averaged $162.1 million across 5 years, with a median of $152.0 million in 2024.
• Across the five-year window, EBIT soared 20800.0% in 2022 and retreated 26.03% in 2024, its largest moves.
• Year by year, EBIT stood at $125.4 million in 2022, then soared by 72.97% to $216.9 million in 2023, then decreased by 12.91% to $188.9 million in 2024, then jumped by 70.99% to $323.0 million in 2025, then dropped by 20.96% to $255.3 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were $255.3 million in Q1 2026, $323.0 million in Q4 2025, and $242.5 million in Q3 2025.